Riskpilot← Back to searchSign inGet full accessDuomedix AB
ABActiveOrg 5591721377Hökarvägen 30Other education n.e.c. · NACE 8559Est. 20181 employees
Revenue 2025
SEK 498K
+21% vs 2024
EBITDA margin
88.4%
+40% vs 2024
Equity ratio
75.6%
Financial strength
Net profit 2025
SEK 348K
+38% vs 2024
| Revenue | SEK 498K | +21% |
| EBITDA | SEK 440K | +40% |
| Net profit | SEK 348K | +38% |
| Total assets | SEK 532K | +28% |
| Equity | SEK 402K | +32% |
| Employees | 1 | — |
Legal name
Duomedix AB
Org number
5591721377
Legal form
Aktiebolag
NACE code
8559 · Other education n.e.c.
Founded
19 september 2018
Share capital
SEK 50 000
Employees
1 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2025-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen Dessutom har verkställande direktören rätt att teckna firman beträffande löpande förvaltningsåtgärder
Company purpose
Företaget ska bedriva konsultverksamhet samt rådgivning, undervisning, författarskap samt utveckling inom medicin samt därmed förenlig verksamhet. Bolaget skall även bedriva handel med värdepapper, fastigheter och fastighetsförvaltning samt med ovan nämnda områden förenlig verksamhet.
Address
Hökarvägen 30
Email
anton.modee.borgstrom@gmail.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 141 | 428 | 530 | 411 | 498 |
| Staff expenses | — | −8 | — | −31 | −25 |
| EBITDA | 115 | 375 | 430 | 314 | 440 |
| Depreciation & amort. | −0 | — | −0 | — | — |
| EBIT | 115 | 375 | 430 | 314 | 440 |
| Net financials | — | — | 1 | 2 | 1 |
| Profit before tax | 115 | 375 | 431 | 316 | 441 |
| Tax | −24 | −77 | −89 | −65 | −94 |
| Net profit | 91 | 298 | 342 | 251 | 348 |
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total assets | 183 | 523 | 564 | 414 | 532 |
| Equity | 145 | 348 | 393 | 304 | 402 |
| Long-term debt | 0 | — | 0 | — | — |
| Short-term debt | 38 | 175 | 171 | 110 | 130 |
| Total debt | 38 | 175 | 171 | 110 | 130 |
EBITDA margin
88.4%
This company
15.8%
Market median
+459% vs market
20212025
Equity ratio
75.6%
This company
38.2%
Market median
+98% vs market
20212025
Return on equity
86.5%
This company
18.4%
Market median
+370% vs market
20212025
Net profit margin
69.8%
This company
8.1%
Market median
+762% vs market
20212025
Asset turnover
0.94×
This company
1.12×
Market median
+16% vs market
20212025
Debt / equity
0.32×
This company
0.62×
Market median
+48% vs market
20212025
- Annual report 2025Filed via Bolagsverket / SCB · Period 2025-01-01 – 2025-12-31
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
NA Chief Executive Officer | Chief Executive Officer | 2021 |
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
| Deputy Board Member | 2022 | |
| Chairman | 2021 | |
| Former (2) | ||
| Deputy Board Member | 2022 – 2022 | |
| Deputy Board Member | 2021 – 2022 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Duomedix AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Nils Anton Johannes Borgström | Chief Executive Officer | 0 companies |
| Julia Fiddeli Elsa Modée | Deputy Board Member | 0 companies |
| Björn Erik Severus Modée Bäcklund | Deputy Board Member | 0 companies |
| Gunnar Magnus Severus Persson | Deputy Board Member | 0 companies |
| Agnes Edith Sofia Modée Borgström | Chairman | 0 companies |